Christopher J Portier

List of Publications by Year
in descending order

179 papers	7,128 citations	71102 41 h-index	66911 78 g-index
189 all docs	189 docs citations	189 times ranked	6615 citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of Chemicals with Endocrine Modulating Activity in a Yeast-Based Steroid Hormone Receptor Gene Transcription Assay. Toxicology and Applied Pharmacology, 1997, 143, 205-212.	2.8	635
2	High-Resolution Air Pollution Mapping with Google Street View Cars: Exploiting Big Data. Environmental Science & Technology, 2017, 51, 6999-7008.	10.0	474
3	Key Characteristics of Carcinogens as a Basis for Organizing Data on Mechanisms of Carcinogenesis. Environmental Health Perspectives, 2016, 124, 713-721.	6.0	415
4	Temperature, air pollution, and hospitalization for cardiovascular diseases among elderly people in Denver.. Environmental Health Perspectives, 2003, 111, 1312-1317.	6.0	267
5	Effects of Treatment-Induced Mortality and Tumor-Induced Mortality on Tests for Carcinogenicity in Small Samples. Biometrics, 1988, 44, 417.	1.4	242
6	Compound Cytotoxicity Profiling Using Quantitative High-Throughput Screening. Environmental Health Perspectives, 2008, 116, 284-291.	6.0	232
7	Human exposure estimates for phthalates.. Environmental Health Perspectives, 2000, 108, A440-2.	6.0	218
8	The Impact of Litter Effects on Dose-Response Modeling in Teratology. Biometrics, 1986, 42, 85.	1.4	170
9	Differences in the carcinogenic evaluation of glyphosate between the International Agency for Research on Cancer (IARC) and the European Food Safety Authority (EFSA). Journal of Epidemiology and Community Health, 2016, 70, 741-745.	3.7	138
10	Evaluation of Biomonitoring Data from the CDC National Exposure Report in a Risk Assessment Context: Perspectives across Chemicals. Environmental Health Perspectives, 2013, 121, 287-294.	6.0	126
11	Characterizing Uncertainty and Variability in Physiologically Based Pharmacokinetic Models: State of the Science and Needs for Research and Implementation. Toxicological Sciences, 2007, 99, 395-402.	3.1	122
12	A Mechanistic Model of Effects of Dioxin on Gene Expression in the Rat Liver. Toxicology and Applied Pharmacology, 1993, 120, 138-154.	2.8	115
13	Dose-Additive Carcinogenicity of a Defined Mixture of â€œDioxin-like Compoundsâ€. Environmental Health Perspectives, 2005, 113, 43-48.	6.0	110
14	Mapping Air Pollution with Google Street View Cars: Efficient Approaches with Mobile Monitoring and Land Use Regression. Environmental Science & Technology, 2018, 52, 12563-12572.	10.0	103
15	Characterization of the proneural gene regulatory network during mouse telencephalon development. BMC Biology, 2008, 6, 15.	3.8	95
16	Global Gene Expression Profiling of a Population Exposed to a Range of Benzene Levels. Environmental Health Perspectives, 2011, 119, 628-640.	6.0	94
17	Characterization of the Doseâ€"Response of CYP1B1, CYP1A1, and CYP1A2 in the Liver of Female Spragueâ€"Dawley Rats Following Chronic Exposure to 2,3,7,8-Tetrachlorodibenzo-p-dioxin. Toxicology and Applied Pharmacology, 1999, 154, 279-286.	2.8	88
18	A Mechanistic Model of Effects of Dioxin on Thyroid Hormones in the Rat. Toxicology and Applied Pharmacology, 1996, 136, 29-48.	2.8	85

#	Article	IF	Citations
19	Using Structural Information to Create Physiologically Based Pharmacokinetic Models for All Polychlorinated Biphenyls. Toxicology and Applied Pharmacology, 1997, 144, 340-347.	2.8	82
20	High-resolution mapping of traffic related air pollution with Google street view cars and incidence of cardiovascular events within neighborhoods in Oakland, CA. Environmental Health, 2018, 17, 38.	4.0	78
21	Pharmacokinetics of Sodium Nitrite-Induced Methemoglobinemia in the Rat. Drug Metabolism and Disposition, 2002, 30, 676-683.	3.3	77
22	The Next Generation of Risk Assessment Multi-Year Studyâ€"Highlights of Findings, Applications to Risk Assessment, and Future Directions. Environmental Health Perspectives, 2016, 124, 1671-1682.	6.0	74
23	The association between biomarker-based exposure estimates for phthalates and demographic factors in a human reference population.. Environmental Health Perspectives, 2002, 110, 405-410.	6.0	72
24	Meeting Report: Moving Upstreamâ€"Evaluating Adverse Upstream End Points for Improved Risk Assessment and Decision-Making. Environmental Health Perspectives, 2008, 116, 1568-1575.	6.0	68
25	Blood lead level association with lower body weight in NHANES 1999â€"2006. Toxicology and Applied Pharmacology, 2013, 273, 516-523.	2.8	67
26	Genetic and environmental pathways to complex diseases. BMC Systems Biology, 2009, 3, 46.	3.0	65
27	Effects of Glutathione Transferase Theta Polymorphism on the Risk Estimates of Dichloromethane to Humans. Toxicology and Applied Pharmacology, 1999, 158, 221-230.	2.8	64
28	Evaluation of toxic equivalency factors for induction of cytochromes P450 CYP1A1 and CYP1A2 enzyme activity by dioxin-like compounds. Toxicology and Applied Pharmacology, 2004, 194, 156-168.	2.8	63
29	The Exact Formula for Tumor Incidence in the Two-Stage Model. Risk Analysis, 1994, 14, 1079-1080.	2.7	60
30	Extended Histopathology in Immunotoxicity Testing: Interlaboratory Validation Studies. Toxicological Sciences, 2004, 78, 107-115.	3.1	56
31	The Accuracy of Extended Histopathology to Detect Immunotoxic Chemicals. Toxicological Sciences, 2004, 82, 504-514.	3.1	55
32	Characterizing Dose-Response I: Critical Assessment of the Benchmark Dose Concept. Risk Analysis, 1998, 18, 13-26.	2.7	53
33	Toxicogenomics: the new frontier in risk analysis. Carcinogenesis, 2002, 23, 903-905.	2.8	53
34	Antinociceptive effects, metabolism and disposition of ketamine in ponies under target-controlled drug infusion. Toxicology and Applied Pharmacology, 2006, 216, 373-386.	2.8	50
35	Modeling the Number and Size of Hepatic Focal Lesions Following Exposure to 2,3,7,8-TCDD. Toxicology and Applied Pharmacology, 1996, 138, 20-30.	2.8	48
36	A Multistage Model of Carcinogenesis Incorporating DNA Damage and Repair. Risk Analysis, 1991, 11, 535-543.	2.7	47

#	Article	IF	Citations
37	Qualitative and quantitative experimental models to aid in risk assessment for immunotoxicology. Toxicology Letters, 1992, 64-65, 71-78.	0.8	47
38	Multiple organ carcinogenicity of inhaled chloroprene (2-chloro-1,3-butadiene) in F344/N rats and B6C3F1 mice and comparison of dose–response with 1,3-butadiene in mice. Carcinogenesis, 1999, 20, 867-878.	2.8	47
39	Application of a Mathematical Model to Describe the Effects of Chlorpyrifos on Caenorhabditis elegans Development. PLoS ONE, 2009, 4, e7024.	2.5	46
40	Low-Dose-Rate Extrapolation Using the Multistage Model. Biometrics, 1983, 39, 897.	1.4	44
41	Birth and death/differentiation rates of papillomas in mouse skin. Carcinogenesis, 1992, 13, 973-978.	2.8	42
42	A comprehensive analysis of the animal carcinogenicity data for glyphosate from chronic exposure rodent carcinogenicity studies. Environmental Health, 2020, 19, 18.	4.0	42
43	Characterizing Elevated Urban Air Pollutant Spatial Patterns with Mobile Monitoring in Houston, Texas. Environmental Science & Technology, 2020, 54, 2133-2142.	10.0	41
44	Human Carcinogenic Risk Evaluation, Part V: The National Toxicology Program Vision for Assessing the Human Carcinogenic Hazard of Chemicals. Toxicological Sciences, 2004, 82, 363-366.	3.1	40
45	What Role for Biologically Based Dose–Response Models in Estimating Low-Dose Risk?. Environmental Health Perspectives, 2010, 118, 585-588.	6.0	40
46	Semiparametric Analysis of Tumor Incidence Rates in Survival/Sacrifice Experiments. Biometrics, 1987, 43, 107.	1.4	39
47	Estimating the tumour onset distribution in animal carcinogenesis experiments. Biometrika, 1986, 73, 371-378.	2.4	38
48	Nonlinearity of dose-response functions for carcinogenicity.. Environmental Health Perspectives, 1994, 102, 109-113.	6.0	37
49	Choosing the right path: enhancement of biologically relevant sets of genes or proteins using pathway structure. Genome Biology, 2009, 10, R44.	9.6	36
50	Approaches for Assessing Risks to Sensitive Populations: Lessons Learned from Evaluating Risks in the Pediatric Population. Toxicological Sciences, 2010, 113, 4-26.	3.1	36
51	Type 1 error of trend tests in proportions and the design of cancer screens. Communications in Statistics - Theory and Methods, 1984, 13, 1-14.	1.0	35
52	Should the presence of carcinogens in breast milk discourage breast feeding?. Regulatory Toxicology and Pharmacology, 1991, 13, 228-240.	2.7	35
53	Calculating tumor incidence rates in stochastic models of carcinogenesis. Mathematical Biosciences, 1996, 135, 129-146.	1.9	35
54	Use of animal studies in risk assessment for immunotoxicology. Toxicology, 1994, 92, 229-243.	4.2	34

#	Article	IF	Citations
55	NTP-CERHR Expert Panel report on the reproductive and developmental toxicity of methanol. Reproductive Toxicology, 2004, 18, 303-390.	2.9	33
56	A Physiologically Based Pharmacokinetic Model for Inhalation and Intravenous Administration of Naphthalene in Rats and Mice. Toxicology and Applied Pharmacology, 2001, 176, 81-91.	2.8	32
57	A Signal-to-Noise Crossover Dose as the Point of Departure for Health Risk Assessment. Environmental Health Perspectives, 2011, 119, 1766-1774.	6.0	32
58	An Evaluation of Some Methods for Fitting Dose-Response Models to Quantal- Response Developmental Toxicology Data. Biometrics, 1993, 49, 779.	1.4	31
59	Gene Interaction Network Suggests Dioxin Induces a Significant Linkage between Aryl Hydrocarbon Receptor and Retinoic Acid Receptor Beta. Environmental Health Perspectives, 2004, 112, 1217-1224.	6.0	31
60	Human consumption of methyleugenol and its elimination from serum.. Environmental Health Perspectives, 2004, 112, 678-680.	6.0	31
61	Achieving a High Level of Protection from Pesticides in Europe: Problems with the Current Risk Assessment Procedure and Solutions. European Journal of Risk Regulation, 2020, 11, 450-480.	1.2	30
62	The application of a multistage model that incorporates DNA damage and repair to the analysis of initiation/promotion experiments. Mathematical Biosciences, 1991, 105, 139-166.	1.9	29
63	AhR-mediated gene expression in the developing mouse telencephalon. Reproductive Toxicology, 2009, 28, 321-328.	2.9	29
64	Estimating the Global Public Health Implications of Electricity and Coal Consumption. Environmental Health Perspectives, 2011, 119, 821-826.	6.0	29
65	Implications for Risk Assessment of Suggested Nongenotoxic Mechanisms of Chemical Carcinogenesis. Environmental Health Perspectives, 1996, 104, 123.	6.0	28
66	Pesticide Testing on Human Subjects: Weighing Benefits and Risks. Environmental Health Perspectives, 2005, 113, 813-817.	6.0	28
67	Inhibition of Human and Pig Ureter Motility in Vitro and in Vivo by the K+ Channel Openers PKF 217-744b and Nicorandil. Journal of Pharmacology and Experimental Therapeutics, 2002, 302, 651-658.	2.5	27
68	Using Structural Information to Create Physiologically Based Pharmacokinetic Models for all Polychlorinated Biphenyls. Toxicology and Applied Pharmacology, 1998, 151, 110-116.	2.8	26
69	A model for hepatocarcinogenesis treating phenotypical changes in focal hepatocellular lesions as epigenetic events. Mathematical Biosciences, 1998, 148, 181-204.	1.9	26
70	Physiological modeling of a proposed mechanism of enzyme induction by TCDD. Toxicology, 2001, 162, 193-208.	4.2	26
71	Effects of the Mechanism of Receptor-Mediated Gene Expression on the Shape of the Dose-Response Curve. Risk Analysis, 1993, 13, 565-572.	2.7	25
72	Stereoselective biotransformation of ketamine in equine liver and lung microsomes. Journal of Veterinary Pharmacology and Therapeutics, 2008, 31, 446-455.	1.3	25

#	Article	IF	Citations
73	Toxicity characterization of environmental chemicals by the US National Toxicology Program: an overview. International Journal of Hygiene and Environmental Health, 2003, 206, 437-445.	4.3	24
74	Report of an ISRTP Workshop: Progress and barriers to incorporating alternative toxicological methods in the U.S.. Regulatory Toxicology and Pharmacology, 2006, 46, 18-22.	2.7	24
75	Carcinoma formation in NMRI mouse skin painting studies is a process suggesting greater than two stages. Carcinogenesis, 1995, 16, 53-59.	2.8	23
76	Gene interaction network analysis suggests differences between high and low doses of acetaminophen. Toxicology and Applied Pharmacology, 2006, 215, 306-316.	2.8	23
77	A Discrete Time Model for the Analysis of Medium-Throughput C. elegans Growth Data. PLoS ONE, 2009, 4, e7018.	2.5	23
78	Issues Concerning the Estimation of the TD50. Risk Analysis, 1987, 7, 437-447.	2.7	22
79	Biostatistical issues in the design and analysis of animal carcinogenicity experiments.. Environmental Health Perspectives, 1994, 102, 5-8.	6.0	22
80	Induction of Lung Lesions in Female Rats Following Chronic Exposure to 2,3,7,8-Tetrachlorodibenzo-p-dioxin. Toxicologic Pathology, 2000, 28, 761-769.	1.8	22
81	Pharmacokinetics and pharmacodynamic effects of amiodarone in plasma of ponies after single intravenous administration. Toxicology and Applied Pharmacology, 2004, 195, 113-125.	2.8	22
82	Dose-Response Modeling of High-Throughput Screening Data. Journal of Biomolecular Screening, 2009, 14, 1216-1227.	2.6	22
83	Concordance between sites of tumor development in humans and in experimental animals for 111 agents that are carcinogenic to humans. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2019, 22, 203-236.	6.5	22
84	Analytic expressions for maximum likelihood estimators in a nonparametric model of tumor incidence and death. Communications in Statistics - Theory and Methods, 1992, 21, 711-732.	1.0	20
85	Risk Assessment in Immunotoxicology. Toxicological Sciences, 1992, 18, 200-210.	3.1	19
86	Absolute estimation of initial concentrations of amplicon in a real-time RT-PCR process. BMC Bioinformatics, 2007, 8, 409.	2.6	19
87	Upstream adverse effects in risk assessment: A model of polychlorinated biphenyls, thyroid hormone disruption and neurological outcomes in humans. Environmental Research, 2012, 117, 90-99.	7.5	19
88	Concordance of Carcinogenic Response between Rodent Species: Potency Dependence and Potential Underestimation. Risk Analysis, 1992, 12, 115-121.	2.7	18
89	The TAO-Gen Algorithm for Identifying Gene Interaction Networks with Application to SOS Repair inE. coli. Environmental Health Perspectives, 2004, 112, 1614-1621.	6.0	18
90	Comparison of Points of Departure for Health Risk Assessment Based on High-Throughput Screening Data. Environmental Health Perspectives, 2017, 125, 623-633.	6.0	18

#	Article	IF	Citations
91	A Measure of Tumorigenic Potency Incorporating Dose-Response Shape. Biometrics, 1993, 49, 917.	1.4	17
92	The Forest for the Trees: A Systems Approach to Human Health Research. Environmental Health Perspectives, 2007, 115, 1261-1263.	6.0	17
93	Building a Robust 21st Century Chemical Testing Program at the U.S. Environmental Protection Agency: Recommendations for Strengthening Scientific Engagement. Environmental Health Perspectives, 2015, 123, 1-5.	6.0	17
94	Multistage, stochastic models of the cancer process: A general theory for calculating tumor incidence. Stochastic Environmental Research and Risk Assessment, 2000, 14, 173-179.	4.0	16
95	Discussion and summary. Radiation Protection Dosimetry, 2008, 132, 273-274.	0.8	16
96	Biological Networks for Predicting Chemical Hepatocarcinogenicity Using Gene Expression Data from Treated Mice and Relevance across Human and Rat Species. PLoS ONE, 2013, 8, e63308.	2.5	16
97	The TAO-Gen Algorithm for Identifying Gene Interaction Networks with Application to SOS Repair in E. coli. Environmental Health Perspectives, 2004, 112, 1614-1621.	6.0	16
98	Replication Potential of Cells via the Protein Kinase C-MAPK pathway: Application of a Mathematical Model. Bulletin of Mathematical Biology, 1999, 61, 379-398.	1.9	15
99	Two‐stage models of tumor incidence for historical control animals in the national toxicology program's carcinogenicity experiments. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1989, 27, 21-45.	2.3	14
100	An Evaluation of the Rai and Van Ryzin Dose-Response Model in Teratology. Risk Analysis, 1991, 11, 111-120.	2.7	14
101	The Importance of Biological Realism in Dioxin Risk Assessment Models Michael. Risk Analysis, 1994, 14, 993-1000.	2.7	14
102	Multistage Models of Carcinogenesis: An Approximation for the Size and Number Distribution of Late-Stage Clones. Risk Analysis, 1994, 14, 1039-1048.	2.7	14
103	Variation in the Hepatic Gene Expression in Individual Male Fischer Rats. Toxicologic Pathology, 2005, 33, 102-110.	1.8	14
104	Re: Tarazona et al. (2017): Glyphosate toxicity and carcinogenicity: a review of the scientific basis of the European Union assessment and its differences with IARC. doi: 10.1007/s00204-017-1962-5. Archives of Toxicology, 2017, 91, 3195-3197.	4.2	14
105	A Note on Approximating the Cumulative Distribution Function of the Time to Tumor Onset in Multistage Models. Biometrics, 1989, 45, 1259.	1.4	13
106	A stem cell model for carcinogenesis. Mathematical Biosciences, 1994, 120, 211-232.	1.9	13
107	Impact of Physiologically Based Pharmacokinetic Modeling on Benchmark Dose Calculations for TCDD-Induced Biochemical Responses. Regulatory Toxicology and Pharmacology, 2002, 36, 287-296.	2.7	13
108	Effects of ketanserin and DOI on spontaneous and 5‐HT‐evoked peristalsis of the pig ureter *in vivo*. British Journal of Pharmacology, 2002, 135, 1026-1032.	5.4	13

#	Article	IF	Citations
109	Uncertainties in Biologically‐Based Modeling of Formaldehyde‐Induced Respiratory Cancer Risk: Identification of Key Issues. Risk Analysis, 2008, 28, 907-923.	2.7	13
110	Expression and function of 5-HT7 receptors in smooth muscle preparations from equine duodenum, ileum, and pelvic flexure. Research in Veterinary Science, 2009, 87, 292-299.	1.9	13
111	Quantitative analysis of multiple phenotype enzyme-altered foci in rat hepatocarcinogenesis experiments: the multipath/multistage model. Carcinogenesis, 1995, 16, 2499-2506.	2.8	12
112	Benchmark Dose Approach. Wiley Series in Probability and Statistics, 2006, , 239-254.	0.0	12
113	Risk Assessment in Immunotoxicology. Toxicological Sciences, 1993, 21, 71-82.	3.1	11
114	Statistical research needs in mechanistic modelling for carcinogenic risk assessment. Statistical Methods in Medical Research, 1997, 6, 305-315.	1.5	10
115	A Mathematical Model of Production, Distribution, and Metabolism of Melatonin in Mammalian Systems. Toxicology and Applied Pharmacology, 1997, 147, 83-92.	2.8	10
116	Calculation of the Cumulative Distribution Function of the Time to a Small Observable Tumor. Bulletin of Mathematical Biology, 2000, 62, 229-240.	1.9	10
117	A Physiologically Based Pharmacokinetic Model of p,p′-Dichlorodiphenylsulfone. Toxicology and Applied Pharmacology, 2002, 181, 153-163.	2.8	10
118	Health, Economy, and Environment: Sustainable Energy Choices for a Nation. Environmental Health Perspectives, 2008, 116, A236-7.	6.0	10
119	Expression and function of 5-hydroxytryptamine 4 receptors in smooth muscle preparations from the duodenum, ileum, and pelvic flexure of horses without gastrointestinal tract disease. American Journal of Veterinary Research, 2010, 71, 1432-1442.	0.6	10
120	Inconclusive Findings: Now You See Them, Now You Don't!. Environmental Health Perspectives, 2014, 122, A36.	6.0	10
121	Explicit solutions for constrained maximum likelihood estimators in survival/sacrifice experiments. Biometrika, 1992, 79, 717-729.	2.4	9
122	Genetic susceptibility: significance in risk assessment. Toxicology Letters, 1998, 102-103, 185-189.	0.8	9
123	Risk ranges for various endpoints following exposure to 2,3,7,8-TCDD. Food Additives and Contaminants, 2000, 17, 335-346.	2.0	9
124	Simulating failure times when the event of interest is unobservable with emphasis on animal carcinogenicity studies. Journal of Biomedical Informatics, 1987, 20, 458-466.	0.7	8
125	Stochastic simulation of a multistage model of carcinogenesis. Mathematical Biosciences, 1996, 134, 35-50.	1.9	8
126	The Two-Stage Model of Carcinogenesis: Overcoming the Nonidentifiability Dilemma. Risk Analysis, 1997, 17, 367-374.	2.7	8

#	Article	IF	Citations
127	Adverse effects in risk assessment: Modeling polychlorinated biphenyls and thyroid hormone disruption outcomes in animals and humans. Environmental Research, 2012, 116, 74-84.	7.5	8
128	An illustration of dangers of ignoring survival differences in carcinogenic data. Journal of Applied Toxicology, 1988, 8, 185-189.	2.8	7
129	A note on fitting one-compartment models: Non-linear least squares versus linear least squares using transformed data. Journal of Applied Toxicology, 1990, 10, 303-306.	2.8	7
130	An Index of Tumorigenic Potency. Biometrics, 1993, 49, 357.	1.4	7
131	Development of a biologically-based controlled growth and differentiation model for developmental toxicology. Journal of Mathematical Biology, 2003, 46, 1-16.	1.9	7
132	Endocrine dismodulation and cancer. Neuroendocrinology Letters, 2002, 23 Suppl 2, 43-7.	0.2	7
133	Incorporating observability thresholds of tumors into the two-stage carcinogenesis model. Mathematical Biosciences, 2000, 163, 75-89.	1.9	6
134	Environmental Predictors of US County Mortality Patterns on a National Basis. PLoS ONE, 2015, 10, e0137832.	2.5	6
135	Species Correlation of Chemical Carcinogens. Risk Analysis, 1988, 8, 551-553.	2.7	5
136	The use of animal tests in risk assessment for immunotoxicology. Toxicology in Vitro, 1994, 8, 945-950.	2.4	5
137	In vitro effects of bethanechol on specimens of intestinal smooth muscle obtained from the duodenum and jejunum of healthy dairy cows. American Journal of Veterinary Research, 2007, 68, 313-322.	0.6	5
138	In vitro effects of bethanechol on smooth muscle preparations from abomasal fundus, corpus, and antrum of dairy cows. Research in Veterinary Science, 2008, 84, 444-451.	1.9	5
139	Potential Effects of Chemical Mixtures on the Carcinogenic Process within the Context of the Mathematical Multistage Model. , 1994, , 665-686.		5
140	Uncertainty in physiological pharmacokinetic modeling and its impact on statistical risk estimation of 2,3,7,8 TCDD. Chemosphere, 1992, 25, 239-242.	8.2	4
141	Mechanistic Modelling and Risk Assessment. Basic and Clinical Pharmacology and Toxicology, 1993, 72, 28-32.	0.0	4
142	Using Cell Replication Data in Mathematical Modeling in Carcinogenesis. Environmental Health Perspectives, 1993, 101, 79.	6.0	4
143	Eyes Closed: Simple, Intuitive, Statistically Sound, and Efficient Methods for Estimating Parameters of Clonal Growth Cancer Models. Risk Analysis, 1998, 18, 529-534.	2.7	4
144	U-shaped dose-response curves for carcinogens. Human and Experimental Toxicology, 1998, 17, 705-707.	2.2	4

#	Article	IF	Citations
145	Testing for Increased Carcinogenicity Using a Survival-Adjusted Quantal Response Test. Toxicological Sciences, 1989, 12, 731-737.	3.1	3
146	Quantitative Mechanistically Based Dose-Response Modeling with Endocrine-Active Compounds. Environmental Health Perspectives, 1999, 107, 631.	6.0	3
147	Identification of a Cardiac Sodium Channel Insensitive to Synthetic Modulators. Journal of Cardiovascular Pharmacology and Therapeutics, 2001, 6, 201-212.	2.0	3
148	A Controlled Growth and Differentiation Model for Non-Monotonic Responses. Human and Ecological Risk Assessment (HERA), 2002, 8, 1739-1755.	3.4	3
149	MtBE and cancer in animals: Statistical issues with poly-3 survival adjustments for lifetime studies. Regulatory Toxicology and Pharmacology, 2008, 50, 428-429.	2.7	3
150	Tackling the Research Challenges of Health and Climate Change. Environmental Health Perspectives, 2009, 117, A534.	6.0	3
151	The Use of Signal-Transduction and Metabolic Pathways to Predict Human Disease Targets from Electric and Magnetic Fields Using in vitro Data in Human Cell Lines. Frontiers in Public Health, 2016, 4, 193.	2.7	3
152	The NIEHS and the National Toxicology Program: An Integrated Scientific Vision. Environmental Health Perspectives, 2005, 113, A440-A440.	6.0	3
153	Insights from application of a hierarchical spatio-temporal model to an intensive urban black carbon monitoring dataset. Atmospheric Environment, 2022, 277, 119069.	4.1	3
154	Cell Proliferation and Chemical Carcinogenesis: Symposium Overview. Environmental Health Perspectives, 1993, 101, 3.	6.0	2
155	Application of a Statistical Dynamic Model Investigating the Short-Term Cellular Kinetics Induced by Riddelliine, a Hepatic Endothelial Carcinogen. Toxicological Sciences, 2004, 80, 258-267.	3.1	2
156	Employing a Mechanistic Model for the Mapk Pathway to Examine the Impact of Cellular all or None Behavior on Overall Tissue Response. Dose-Response, 2010, 8, dose-response.0.	1.6	2
157	A simple procedure for estimating pseudo risk ratios from exposure to non-carcinogenic chemical mixtures. Archives of Toxicology, 2016, 90, 513-523.	4.2	2
158	Elucidating environmental dimensions of neurological disorders and disease: Understanding new tools from federal chemical testing programs. Science of the Total Environment, 2017, 593-594, 634-640.	8.0	2
159	Gene Expression Networks. Methods in Molecular Biology, 2013, 930, 165-178.	0.9	2
160	Comments on the International Symposium on Light, Endocrine Systems and Cancer. Neuroendocrinology Letters, 2002, 23 Suppl 2, 79-81.	0.2	2
161	Life Table Analysis of Carcinogenicity Experiments. Journal of the American College of Toxicology, 1988, 7, 575-582.	0.2	1
162	Linking toxicology and epidemiology: the role of mechanistic modelling. Statistics in Medicine, 2001, 20, 1387-1393.	1.6	1

#	Article	IF	Citations
163	4 Toxicological decision-making on hazards and risks â€" status quo and way forward. Human and Experimental Toxicology, 2009, 28, 123-125.	2.2	1
164	Comprehensive Environmental Public Health. Public Health Reports, 2011, 126, 3-6.	2.5	1
165	Signal-To-Noise Crossover Dose: Sand et al. Respond. Environmental Health Perspectives, 2012, 120, .	6.0	1
166	Building a Framework to Identify Global Health Impacts of Power Generation Systems. Epidemiology, 2009, 20, S263.	2.7	1
167	U-shaped dose-response curves for carcinogens. Human and Experimental Toxicology, 1998, 17, 705-707.	2.2	1
168	Filling the Translationâ€"Policy Gap. Environmental Health Perspectives, 2007, 115, A125-A125.	6.0	1
169	Association between traffic related air pollution exposure and direct health care costs in Northern California. Atmospheric Environment, 2022, 287, 119271.	4.1	1
170	Design of Animal Carcinogenicity Studies for Goodness-of-Fit of Multistage Models. Toxicological Sciences, 1984, 4, 949-959.	3.1	0
171	Type 1 Error and Power of the Linear Trend Test in Proportions under the National Toxicology Program's Modified Pathology Protocol. Toxicological Sciences, 1986, 6, 515-519.	3.1	0
172	Variability of Safe Dose Estimates When Using Complicated Models of the Carcinogenic Process. Toxicological Sciences, 1989, 13, 533-544.	3.1	0
173	Two-Stage Models of Carcinogenesis, Classification of Agents, and Design of Experiments. Toxicological Sciences, 1990, 14, 444-460.	3.1	0
174	Distinguishing between Models of Carcinogenesis: The Role of Clonal Expansion. Toxicological Sciences, 1991, 17, 601-613.	3.1	0
175	Immunologic Findings in Workers Formerly Exposed to 2,3,7,8-Tetrachlorodibenzo-p-Dioxin and Its Congeners. Environmental Health Perspectives, 1998, 106, 689.	6.0	0
176	COMMENTS ON A BIOCHEMICAL MODEL OF CYCLOPHOSPHAMIDE HEMATOTOXICITY. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2000, 61, 525-528.	2.3	0
177	Pesticide Testing on Humans: Resnick and Portier Respond. Environmental Health Perspectives, 2005, 113, .	6.0	0
178	Dose-Response Modeling for 2,3,7,8-Tetrachlorodibenzo-p-Dioxin. , 2005, , 247-298.		0
179	Pesticide Testing on Humans: Resnick and Portier Respond. Environmental Health Perspectives, 2005, 113, A805-A805.	6.0	0